Clinical Trial Search

Primary: Subjective Rating of Marijuana Craving on 1-7 Likert Scale — 1.64; 0.80 units on a scale

Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — -334.21; -359.95 ng/mg

Primary: Percent Marijuana-negative Urine Drug Screens (UDS) — 7.2; 6.4 percentage of UDS

Primary: Percent Marijuana-negative Urine Drug Screens (UDS) — 5.5; 3.6 percentage of UDS

Primary: Withdrawal Symptom Severity on the Marijuana Withdrawal Checklist (MWC) at 28 Days Following Single Dose Administration of Rimonabant or Placebo, or Commencement of…

Primary: Maximum Tolerated Dose of Quetiapine — 197 milligrams

Primary: Consecutive Weeks of Marijuana Abstinence — 3.55; 2.82; 0.78 consecutive weeks of abstinence — p=<0.05

Primary: Change From Baseline in Cannabis Use at 10 Weeks — 268.8; 286.7; 490.3; 216.9 Ratio

Primary: Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study — 14.00; 7.00; 10.00; 8.00 dollars

Primary: Urine Drug Screen — 0; 0 Participants

Primary: Peak Effect of Marijuana Withdrawal — 4.6; 4.1; 2.9; 1.7 units on a scale

Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 12 — -966.00; -532.81 ng/ml — p=.029

Primary: Cigarette Use — 12.6; 2.1 cigarettes/day

Primary: Percentage of Negative Urinary Drug Screens (UDS) for Cannabis at 12 Weeks Following Administration of Gabapentin or Placebo During the Double Blind Period — 11.22…

Primary: Profile of Mood Scale Total Negative Affect (Tension + Depression + Anger) — 8.52; 8.096; 5.14; 4.615 units on a scale

Primary: Validity of the Marijuana Purchase Task (MPT) — 63 percentage of participants — p=.00000004

Primary: Reduction in Mean Number of Days of Cannabis Use Per Week — 4.1; 3.1 days of use per week

Primary: Marijuana Abstinence (2 Weeks or Greater) — 72.5; 68.6; 45.1 percentage of participants

Primary: Alcohol Craving — 2.54; 2.64; 2.65; 2.55 units on a scale

Primary: Proportion of Patients Abstinent From Marijuana During Weeks 7 and 8 of the Trial — 14; 12 participants

Primary: Tolerability — 0; 0; 0 Participants

Primary: 21 Days of Consecutive Abstinence as Measured by the Time-line Followback. — 18; 17 participants

Primary: Change in Marijuana Use — -1.7 days

Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — 198.3; 55.9 ng/mg

Primary: Physiological Changes in Response to Cue-induced Craving. — 5.65 T value

Primary: Subjective Craving of Marijuana — 50.5; 52.3 Scores on a Scale

Primary: Marijuana Use — 2.5; 3.9 Reported uses per day

Primary: Efficacy of Varenicline vs. Placebo for Reducing Total Number of Weekly Cannabis Use Sessions — 10.3; 11.6; 9.4; 11.7 number of weekly use sessions

Primary: Self-Administration of Drug Units Earned — 0.00; 3.83; 3.67; 0.00 Number of drug units

Primary: Estimated Week 12 Self-reported Use — 2.17; 1.84 Times per day